ClinicalTrials.gg
TerminatedNCT06810375Updated Nov 17, 2026

Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery

A Phase 3 interventional study of Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) and Intercostal nerve block in Lung Cancers, sponsored by George Washington University. Terminated at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by George Washington University · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The IRB for this study has been closed and the PI left the institution.
Updated Nov 17, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,462 studies in Lung Neoplasms with a site in United States — 423 open to participants now, 644 under way, 52 of them phase 3. Lung Neoplasms · United States.

Enrollment
1,543rd of 1,908
14 · median 48
Started
2025
with 103 others
Phase 3
158 of 2,462
23 open now
Registered
2,281st of 2,462
by date

Among the 2,462 studies in Lung Neoplasms with a site in United States, this one is the 1,543rd largest by enrollment of the 1,908 interventional ones that give a count, is one of 104 that started in 2025, is one of 158 in phase 3, and was the 2,281st registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

423 of the 2,462 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

418 more — sign in →

All 423 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,462 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.

03

Conditions studied

  • Lung Cancers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Video assisted pulmonary resection, pleurodesis or decortication

Exclusion criteria

Exclusion Criteria:

  • Allergy to local anesthetics
  • Patient undergoing bilateral surgery
  • Surgery is emergent as deemed by the principal investigator
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Active comparator
    Preoperative Erector Spinae Block (ESB)(Bupivacaine)(Marcaine®)

    Drug: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) · Drug: Intercostal nerve block

  • Active comparator
    Intraoperative Intercostal Nerve Block (INB)(Liposomal Bupivacaine)(Exparel®)

    Drug: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) · Drug: Intercostal nerve block

Interventions

  • DrugErector Spinae (ESP) Block with Bupivacaine (Marcaine®)

    Drug page: BupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    preoperative erector spinae block with bupivacaine (Marcaine®)

  • DrugIntercostal nerve block

    intraoperative intercostal nerve block with liposomal bupivacaine (Exparel®)

06

What researchers measure

Primary outcomes

  1. Postoperative pain control assessment

    Study team will assess postoperative pain scores at 6, 12, 24 and 48 hours (Minimum numerical pain score of 0 and a maximum of 10)

    Time frame: Up to 48 hours postoperatively

  2. Morphine equivalent assessment

    Study team will collect information on all administered pain medications to calculate morphine equivalents

    Time frame: Up to 72 hours postoperatively

Secondary outcomes

  1. Postoperative pain control assessment

    Study team will assess postoperative pain scores at 72 hours (Minimum numerical pain score of 0 and a maximum of 10)

    Time frame: Up to 72 hours postoperatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2025 to primary completion in Nov 2026, 20 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Feb 2028 → Nov 2026 and completion Feb 2029 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Feb 5, 2025
StartActual
Mar 1, 2025
Primary completionActual
Nov 2, 2026was Feb 2028
CompletionActual
Nov 2, 2026was Feb 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The IRB for this study has been closed and the PI left the institution.
changed Nov 17, 2026
Primary completion
Feb 28, 2028→Nov 2, 2026 (actual)
Nov 17, 2026
Study completion
Feb 28, 2029→Nov 2, 2026 (actual)
Nov 17, 2026
Enrollment
120 (estimated)→14 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Terminated
    Why stopped The IRB for this study has been closed and the PI left the institution.
    Primary completion Feb 28, 2028→Nov 2, 2026 (now actual)
    Study completion Feb 28, 2029→Nov 2, 2026 (now actual)
    Enrollment 120 (estimated)→14 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06810375
Responsible party
Akhil Patel (MD, Principal Investigator, George Washington University) — Principal investigator
First posted
Feb 5, 2025
Start date
Mar 1, 2025
Primary completion
Nov 2, 2026
Completion
Nov 2, 2026
Last update
Nov 17, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion